Veklury (Remdesivir) Patent Expiration, LOE Window & CMS Spending

Veklury (Remdesivir) by Gilead Sciences: FDA Orange Book core substance LOE 2036-04-29 (last listed 2041-11-28), 0 AB generics, $2.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN214787 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-04-29
Last Listed Patent or Exclusivity Date2041-11-28
Orange Book Patents (*PED Extensions)32 patents (16 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.7M
2024 Medicare Part D Spend$381K
2024 Medicaid Spend$2.3M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 18.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.